Vanguard Personalized Indexing Management LLC Has $906,000 Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Vanguard Personalized Indexing Management LLC trimmed its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 24.6% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 70,168 shares of the company’s stock after selling 22,911 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Takeda Pharmaceutical were worth $906,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Capital Research Global Investors raised its position in Takeda Pharmaceutical by 3.6% during the fourth quarter. Capital Research Global Investors now owns 14,297,805 shares of the company’s stock valued at $204,030,000 after purchasing an additional 503,446 shares in the last quarter. Mondrian Investment Partners LTD lifted its stake in Takeda Pharmaceutical by 47.9% in the 1st quarter. Mondrian Investment Partners LTD now owns 12,079,962 shares of the company’s stock valued at $169,119,000 after purchasing an additional 3,912,569 shares during the last quarter. Van ECK Associates Corp boosted its position in Takeda Pharmaceutical by 21.1% in the second quarter. Van ECK Associates Corp now owns 2,040,829 shares of the company’s stock valued at $26,408,000 after buying an additional 356,069 shares in the last quarter. OLD Mission Capital LLC grew its stake in shares of Takeda Pharmaceutical by 1,440.9% during the fourth quarter. OLD Mission Capital LLC now owns 1,041,526 shares of the company’s stock worth $14,863,000 after buying an additional 973,935 shares during the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Takeda Pharmaceutical by 1.7% during the fourth quarter. Wells Fargo & Company MN now owns 774,552 shares of the company’s stock worth $11,053,000 after buying an additional 12,756 shares in the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Up 0.7 %

NYSE TAK opened at $14.91 on Tuesday. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $16.06. The business’s fifty day moving average is $14.35 and its 200 day moving average is $13.75. The company has a quick ratio of 0.74, a current ratio of 1.26 and a debt-to-equity ratio of 0.65. The company has a market cap of $47.19 billion, a price-to-earnings ratio of 27.11, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.19. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. The company had revenue of $7.75 billion for the quarter. As a group, sell-side analysts expect that Takeda Pharmaceutical Company Limited will post 1.63 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.